Sage Therapeutics (SAGE) Set to Announce Quarterly Earnings on Thursday

Sage Therapeutics (NASDAQ:SAGE) is scheduled to post its quarterly earnings results before the market opens on Thursday, April 25th. Analysts expect Sage Therapeutics to post earnings of ($1.58) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.28) by $0.73. Sage Therapeutics had a negative net margin of 626.32% and a negative return on equity of 54.41%. The firm had revenue of $77.97 million during the quarter, compared to analyst estimates of $60.15 million. During the same quarter in the prior year, the business posted ($2.47) earnings per share. The company’s quarterly revenue was up 2621.5% compared to the same quarter last year. On average, analysts expect Sage Therapeutics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Sage Therapeutics Stock Up 0.5 %

NASDAQ:SAGE opened at $12.95 on Wednesday. The firm has a market capitalization of $778.42 million, a PE ratio of -1.43 and a beta of 0.86. The firm has a 50-day moving average price of $19.22 and a 200 day moving average price of $20.78. Sage Therapeutics has a 12-month low of $10.92 and a 12-month high of $59.99.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on SAGE shares. Bank of America lowered shares of Sage Therapeutics from a “neutral” rating to an “underperform” rating and dropped their price objective for the stock from $24.00 to $14.00 in a report on Wednesday, April 17th. Oppenheimer dropped their price objective on shares of Sage Therapeutics from $25.00 to $17.00 and set a “market perform” rating for the company in a report on Thursday, April 18th. Royal Bank of Canada raised their price objective on shares of Sage Therapeutics from $21.00 to $26.00 and gave the stock a “sector perform” rating in a report on Thursday, February 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a report on Thursday, April 18th. Finally, StockNews.com lowered shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, April 19th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $39.28.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.